Sun Pharma Q4 FY26 results on May 22: key dates

What Sun Pharma has announced

Sun Pharmaceutical Industries Ltd has scheduled its financial results for the quarter ended 31 March 2026 (Q4 FY26) for 22 May 2026, along with an investor conference call later the same day. The company said the audited standalone and consolidated financial results for the quarter and year ended 31 March 2026 will be considered and approved at a board meeting on Friday, 22 May 2026. An intimation under Regulation 30 (LODR) also sets out the structure of the earnings call and the process for participants to join. The results are expected to be published on the company website, www.sunpharma.com. The company’s communication to stock exchanges on this schedule was dated 13 May 2026. Separately, an “Analyst / Investor Meet” intimation is timestamped 08 May 2026 at 07:50 PM.

Earnings call timing and how to access it

Sun Pharma has planned an hour-long earnings conference call at 06:30 pm IST on 22 May 2026. Senior management will discuss the company’s performance and respond to questions from participants. Investors have been advised to pre-register and to dial in five to ten minutes before the scheduled start. The operator will share instructions on the Q and A process before the call begins. The company also said the call may be available via an audio webcast, with details to be announced on its website. A transcript of the conference call will also be made available on www.sunpharma.com following the event.

Key Q3 FY26 profit and operating signals

Ahead of the Q4 print, Sun Pharma’s most recent disclosed quarter in the provided data shows a clear profit uptick. Net profit in Q3 2025-2026 rose 16.03% year-on-year to ₹3,368.81 crore. On a sequential basis, net profit increased 8.05% versus the prior quarter. The company’s EBITDA for Q3 was reported at ₹4,984.4 crore, up 23.4% from ₹4,009 crore a year earlier. These figures frame the expectations heading into the January to March quarter, especially as Q4 is often watched closely for year-end execution.

Dividend data investors are tracking

For the quarter ending December 2025, Sun Pharma declared a dividend of ₹11.00 per share on 31 Jan 2026. The data provided translates that payout into a dividend yield of 1.43%. Investors typically watch for updates on dividend recommendations when the board meets to approve annual audited results. In the current disclosures, the company noted it will recommend a dividend, if any, on Friday, 22 May 2026.

What the financial snapshot shows (converted to ₹ crore)

The provided snapshot includes a high-level revenue and earnings view. Values stated in billions have been converted to a single base unit of ₹ crore for comparability.

Street expectations for Q4 FY26 (as stated)

Multiple brokerage previews cited in the supplied text place Q4 FY26 revenue estimates in the range of ₹14,500 crore to ₹15,500 crore. Profit after tax (PAT) expectations are stated at ₹2,900 crore to ₹3,200 crore. EBITDA margin projections in these notes are 28% to 30%. One comparison point included is Q3 FY26 revenue of ₹13,897 crore, which the estimates use as the base for expected sequential growth. The same set of notes also references projected momentum in US specialty growth of 12% to 15% year-on-year.

Dates confusion: May 19 vs May 22

While the company’s exchange-linked disclosures in the provided text set the results and call for 22 May 2026, some parts of the supplied material also state that Sun Pharma “has scheduled its Q4 FY26 results for May 19, 2026” and that the board will meet on that date. The text also separately lists “Next Earnings Date: May 22, 2026” and includes the earnings call details for 22 May 2026 at 06:30 pm IST. Given the mixed references, investors typically rely on the latest exchange filing and the company’s website updates for the final schedule.

What investors should watch on results day

The Q4 release is expected to include audited standalone and consolidated numbers for both the quarter and the full financial year ended 31 March 2026. Alongside headline revenue and profit, market participants generally focus on operating margin movement, any commentary tied to execution, and the board’s stance on dividend recommendation. The company also indicated that results will be made available on www.sunpharma.com, and that a call transcript will follow the conference call. Another data point in the supplied material is that the last quarter’s EPS was 12.00 INR against an estimate of 12.52 INR, and the next quarter EPS is expected at 12.41 INR. The same set of figures indicates “next quarter” revenue expected at ₹14,234 crore (converted from 142.34B INR), which is broadly within the range of Q4 preview estimates cited.

Key details for participants and contact points

The dial-in numbers and contacts shared by the company provide the operational details investors often need on results day.

Market impact and why the event matters

For Sun Pharma shareholders, a scheduled audited results day can affect near-term trading because it concentrates updates on profitability, margins, and capital allocation in a single event. In the provided analyst commentary, there is an explicit warning that a revenue miss of 3% to 5% could lead to a 5% to 8% decline in the share price post-results, highlighting the sensitivity to reported numbers versus expectations. The stock’s one-year return is also cited at -3% in the supplied material, which increases attention on management commentary and any fiscal-year guidance references. Against this backdrop, Q3 showed net profit of ₹3,368.81 crore with 16.03% year-on-year growth and EBITDA of ₹4,984.4 crore, up 23.4% year-on-year, setting a strong comparison base for Q4.

Conclusion

Sun Pharma’s Q4 FY26 results are scheduled for 22 May 2026, with an earnings call at 06:30 pm IST the same day and follow-up materials to be hosted on www.sunpharma.com. The market will track audited full-year numbers, any dividend recommendation, and management’s discussion of performance during the conference call. Analyst previews in the provided text point to Q4 revenue of ₹14,500 crore to ₹15,500 crore and PAT of ₹2,900 crore to ₹3,200 crore, with EBITDA margins projected at 28% to 30%. Investors planning to participate can use the dial-in details and pre-registration guidance shared in the company’s intimation, and watch for the webcast link and transcript after the event.